Consortium Reports Results of Challenge to Establish Benchmark for Tumor Mutation Calling | GenomeWeb

NEW YORK (GenomeWeb) – Next-generation sequencing technologies and bioinformatics pipelines keep improving, yet calling somatic mutations from tumor samples still remains a challenge, as evidenced by recent data from The Cancer Genome Atlas showing that four major genome centers only agreed on 31 percent of SNV calls in lung cancer samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.